JP2008525433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525433A5 JP2008525433A5 JP2007548145A JP2007548145A JP2008525433A5 JP 2008525433 A5 JP2008525433 A5 JP 2008525433A5 JP 2007548145 A JP2007548145 A JP 2007548145A JP 2007548145 A JP2007548145 A JP 2007548145A JP 2008525433 A5 JP2008525433 A5 JP 2008525433A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- suspension
- form according
- granules
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 24
- 239000008187 granular material Substances 0.000 claims 24
- 239000000725 suspension Substances 0.000 claims 18
- 239000003085 diluting agent Substances 0.000 claims 8
- 239000003349 gelling agent Substances 0.000 claims 7
- 239000007788 liquid Substances 0.000 claims 7
- 239000012669 liquid formulation Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000008188 pellet Substances 0.000 claims 4
- 229940126409 proton pump inhibitor Drugs 0.000 claims 4
- 239000000612 proton pump inhibitor Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 239000011247 coating layer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 210000004211 gastric acid Anatomy 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 229960000381 omeprazole Drugs 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 229920005596 polymer binder Polymers 0.000 claims 2
- 239000002491 polymer binding agent Substances 0.000 claims 2
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical group N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000011162 core material Substances 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical group C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 159000000011 group IA salts Chemical class 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 208000000689 peptic esophagitis Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000009498 subcoating Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229950008375 tenatoprazole Drugs 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63843504P | 2004-12-22 | 2004-12-22 | |
| US60/638,435 | 2004-12-22 | ||
| PCT/SE2005/001972 WO2006068596A1 (en) | 2004-12-22 | 2005-12-20 | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008525433A JP2008525433A (ja) | 2008-07-17 |
| JP2008525433A5 true JP2008525433A5 (enExample) | 2009-02-05 |
| JP5171259B2 JP5171259B2 (ja) | 2013-03-27 |
Family
ID=36602062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548145A Expired - Lifetime JP5171259B2 (ja) | 2004-12-22 | 2005-12-20 | プロトンポンプインヒビターを包含する固形剤形およびそれから調製された懸濁剤 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20060134210A1 (enExample) |
| EP (1) | EP1830816B1 (enExample) |
| JP (1) | JP5171259B2 (enExample) |
| KR (1) | KR101321641B1 (enExample) |
| CN (1) | CN101087590B (enExample) |
| AR (1) | AR052173A1 (enExample) |
| AU (1) | AU2005319732B2 (enExample) |
| BR (1) | BRPI0519186A2 (enExample) |
| CA (1) | CA2592030C (enExample) |
| CY (1) | CY1113207T1 (enExample) |
| DK (1) | DK1830816T3 (enExample) |
| ES (1) | ES2389844T3 (enExample) |
| HR (1) | HRP20120719T1 (enExample) |
| IL (1) | IL183658A (enExample) |
| ME (1) | ME01458B (enExample) |
| MX (1) | MX2007007423A (enExample) |
| MY (1) | MY149156A (enExample) |
| NO (1) | NO20073731L (enExample) |
| NZ (1) | NZ555833A (enExample) |
| PL (1) | PL1830816T3 (enExample) |
| PT (1) | PT1830816E (enExample) |
| RS (1) | RS52472B (enExample) |
| RU (1) | RU2397756C2 (enExample) |
| SA (1) | SA05260421B1 (enExample) |
| SI (1) | SI1830816T1 (enExample) |
| TW (1) | TWI478735B (enExample) |
| UA (1) | UA87341C2 (enExample) |
| WO (1) | WO2006068596A1 (enExample) |
| ZA (1) | ZA200705113B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
| US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| US8241664B2 (en) | 2005-04-15 | 2012-08-14 | Clarus Therapeutics, Inc | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| AU2007317561A1 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
| AU2009215514B9 (en) | 2008-02-20 | 2014-01-30 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
| WO2009114365A2 (en) * | 2008-03-13 | 2009-09-17 | Mallinckrodt Inc. | Multi-function, foot-activated controller for imaging system |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| JP2012072061A (ja) * | 2009-01-29 | 2012-04-12 | Eisai R & D Management Co Ltd | 新規組成物 |
| US20130052278A1 (en) * | 2010-03-11 | 2013-02-28 | Rich Vitamins Llc | Quick dissolve nutritional powder |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| GB201306720D0 (en) | 2013-04-12 | 2013-05-29 | Special Products Ltd | Formulation |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| US12472149B2 (en) | 2015-07-17 | 2025-11-18 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
| EP3117824A1 (en) | 2015-07-17 | 2017-01-18 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
| US20190008787A1 (en) | 2015-07-17 | 2019-01-10 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
| WO2017145146A1 (en) * | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| CN107468652A (zh) * | 2016-06-07 | 2017-12-15 | 北京新领先医药科技发展有限公司 | 一种固体干混悬温敏凝胶剂及其制备方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US10946002B2 (en) * | 2016-10-06 | 2021-03-16 | Jubilant Generics Limited | Pharmaceutical suspension dosage form of benzimidazole compounds and process of preparation thereof |
| US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| CN108201527A (zh) * | 2016-12-16 | 2018-06-26 | 广州共禾医药科技有限公司 | 一种包含质子泵抑制剂的缓释干混悬剂及其制备方法 |
| AU2019308326B2 (en) | 2018-07-20 | 2025-07-31 | Lipocine Inc. | Liver disease |
| CN116096352A (zh) * | 2020-06-10 | 2023-05-09 | 阿帕亚知识产权公司 | 含有与胶凝剂组合的多个剂型的肠因子释放物质的药物组合物 |
| JP6964369B1 (ja) * | 2021-02-10 | 2021-11-10 | 共和薬品工業株式会社 | 速崩壊性ゲル皮膜 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1183574B (it) * | 1985-05-08 | 1987-10-22 | Eurand Spa | Metodo per ottenere una sospensione estemporanea omogenea di microcapsule |
| US4704285A (en) * | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
| GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
| US5288500A (en) * | 1987-03-13 | 1994-02-22 | Benzon Pharma A/S | Oral composition containing particles comprising an active substance |
| DK130287D0 (da) * | 1987-03-13 | 1987-03-13 | Benzon As Alfred | Oralt praeparat |
| IT1246350B (it) * | 1990-07-11 | 1994-11-17 | Eurand Int | Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili |
| DK0661966T3 (da) * | 1991-12-17 | 2000-10-16 | Biovail Tech Ltd | Sammensætning og fremgangsmåde til ulcusforebyggelse og - behandling |
| SE9301489D0 (sv) * | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| US5840737A (en) * | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| DE69727922T2 (de) * | 1996-04-16 | 2005-01-20 | Novartis Consumer Health S.A. | Schnell zerfallende orale dosierungsform |
| GB2318511A (en) * | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
| US6362009B1 (en) * | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| HUP0100065A2 (hu) * | 1997-12-08 | 2001-08-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma |
| US6013821A (en) * | 1998-06-25 | 2000-01-11 | Abbott Laboratories | Removal of silylated compounds from solvent and gas waste streams |
| US6194395B1 (en) * | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| JP4980527B2 (ja) * | 1999-06-07 | 2012-07-18 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸に不安定な活性化合物を含有する新規の製剤および投与形 |
| WO2001022940A1 (en) * | 1999-09-30 | 2001-04-05 | Edward Mendell Co., Inc. | Sustained release matrix systems for highly soluble drugs |
| EP1232746B1 (en) * | 2001-02-14 | 2006-06-14 | Forte IQ B.V. | Pharmaceutical composition comprising xanthan gum |
| TWI259836B (en) * | 2001-04-12 | 2006-08-11 | Astrazeneca Ab | Modified release formulation suitable for antiarrhythmic compounds |
| US6605302B2 (en) * | 2001-07-17 | 2003-08-12 | Osmotica Corp. | Drug delivery device containing oseltamivir and an H1 antagonist |
| US20040081700A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Dose titratable liquid dosage forms of acid labile drugs |
| US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040005362A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040006109A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| US20040081671A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| WO2005011637A1 (ja) * | 2003-08-04 | 2005-02-10 | Eisai Co., Ltd. | 用時分散型製剤 |
| US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| CN101223129A (zh) * | 2005-07-15 | 2008-07-16 | 惠氏公司 | 高度选择性血清素和去甲肾上腺素双重再摄取抑制剂和其用途 |
-
2005
- 2005-12-19 US US11/312,869 patent/US20060134210A1/en not_active Abandoned
- 2005-12-20 DK DK05820824.0T patent/DK1830816T3/da active
- 2005-12-20 BR BRPI0519186-6A patent/BRPI0519186A2/pt not_active IP Right Cessation
- 2005-12-20 PL PL05820824T patent/PL1830816T3/pl unknown
- 2005-12-20 UA UAA200706656A patent/UA87341C2/uk unknown
- 2005-12-20 MY MYPI20056059A patent/MY149156A/en unknown
- 2005-12-20 WO PCT/SE2005/001972 patent/WO2006068596A1/en not_active Ceased
- 2005-12-20 SI SI200531586T patent/SI1830816T1/sl unknown
- 2005-12-20 CA CA2592030A patent/CA2592030C/en not_active Expired - Fee Related
- 2005-12-20 RS RS20120403A patent/RS52472B/sr unknown
- 2005-12-20 US US11/722,387 patent/US20080020053A1/en not_active Abandoned
- 2005-12-20 AU AU2005319732A patent/AU2005319732B2/en not_active Expired
- 2005-12-20 ES ES05820824T patent/ES2389844T3/es not_active Expired - Lifetime
- 2005-12-20 RU RU2007127781/15A patent/RU2397756C2/ru active
- 2005-12-20 KR KR1020077014098A patent/KR101321641B1/ko not_active Expired - Fee Related
- 2005-12-20 CN CN2005800441944A patent/CN101087590B/zh not_active Expired - Lifetime
- 2005-12-20 SA SA05260421A patent/SA05260421B1/ar unknown
- 2005-12-20 PT PT05820824T patent/PT1830816E/pt unknown
- 2005-12-20 JP JP2007548145A patent/JP5171259B2/ja not_active Expired - Lifetime
- 2005-12-20 ME MEP-2012-106A patent/ME01458B/me unknown
- 2005-12-20 HR HRP20120719TT patent/HRP20120719T1/hr unknown
- 2005-12-20 NZ NZ555833A patent/NZ555833A/en not_active IP Right Cessation
- 2005-12-20 AR ARP050105374A patent/AR052173A1/es not_active Application Discontinuation
- 2005-12-20 EP EP05820824A patent/EP1830816B1/en not_active Expired - Lifetime
- 2005-12-20 MX MX2007007423A patent/MX2007007423A/es active IP Right Grant
- 2005-12-22 TW TW094145910A patent/TWI478735B/zh active
-
2007
- 2007-06-04 IL IL183658A patent/IL183658A/en not_active IP Right Cessation
- 2007-06-18 ZA ZA2007/05113A patent/ZA200705113B/en unknown
- 2007-07-18 NO NO20073731A patent/NO20073731L/no not_active Application Discontinuation
-
2012
- 2012-09-26 CY CY20121100881T patent/CY1113207T1/el unknown
-
2013
- 2013-06-05 US US13/910,780 patent/US20130273168A1/en not_active Abandoned
-
2014
- 2014-12-03 US US14/559,532 patent/US20150079186A1/en not_active Abandoned
-
2017
- 2017-02-10 US US15/429,258 patent/US20170165248A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525433A5 (enExample) | ||
| RU2007127781A (ru) | Твердая лекарственная форма, содержащая ингибитор протонного насоса, и получаемая из нее суспензия | |
| JP4885347B2 (ja) | 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤 | |
| RU2240110C2 (ru) | Новый препарат | |
| JP4638964B2 (ja) | プロトンポンプ阻害剤およびｎｓａｉｄからなる経口用医薬剤形 | |
| JP4789806B2 (ja) | パントプラゾール多粒子処方 | |
| MXPA02002197A (es) | Formas de administracion farmaceuticas orales con accion retardada. | |
| TW201041608A (en) | Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs | |
| JP2001526213A (ja) | 経口医薬パルス放出剤形 | |
| AU742620B2 (en) | R-lansoprazole compositions and methods | |
| SG190905A1 (en) | Orally disintegrating tablet | |
| CN108904462A (zh) | 双用途硫酸盐口服药物组合物片剂及其使用方法 | |
| CN100393304C (zh) | 一种包含酸不稳定药物的微细颗粒及其制剂 | |
| CN102836167B (zh) | 一种复方庆大霉素普鲁卡因胃漂浮缓释微丸 | |
| WO1999000112A1 (en) | Sucralfate-containing composition and process for the preparation thereof | |
| JP2683454B2 (ja) | 固形制酸剤及びその製造法 | |
| CN101277680A (zh) | 苦味活性成分的口腔分散片剂 | |
| CN106619550B (zh) | 一种含有兰索拉唑的肠溶口崩片剂及其制备方法 | |
| JPWO1995033469A1 (ja) | 固形制酸剤及びその製造法 | |
| JPWO1999000112A1 (ja) | スクラルファート含有組成物及びその製造方法 | |
| HK1111609B (en) | Solid dosage form comprising proton pump inhibitor and suspension made thereof |